Abstract
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Both the 4-dose (Zagreb) and 5-dose (Essen) rabies vaccination regimens demonstrate comparable immunogenicity and safety profiles in clinical trials and are approved for use in China. WHAT IS ADDED BY THIS REPORT? This study pioneers active safety surveillance via a mobile application, identifying an adverse reaction rate of 2.10% for the Zagreb regimen and 2.70% for the Essen regimen. The Zagreb regimen had a lower out-of-window administration rate of 8.41% compared to 16.38%. Compliance was influenced by age, marital status, and exposure level, while the Essen regimen involved additional factors, including education level and perceived convenience. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? This study supports broader adoption of the 4-dose regimen to reduce logistical challenges and enhance compliance. Mobile application-based active surveillance presents a novel approach to enhancing real-world monitoring quality.